Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 11, 2011, Pages 2335-2342

  Badot, V ^a,b   Durez, P ^a   Van den Eynde, B J ^c   Nzeusseu Toukap, A ^a   Houssiau, F A ^a   Lauwerys, B R ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

Biomarker; Interleukin 7 receptor chain; Rheumatoid arthritis; TNF blockade

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 7 RECEPTOR; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; BIOSYNTHESIS; BLOOD; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; FEMALE; FIBROBLAST; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RHEUMATOID ARTHRITIS; SYNOVIUM;

ADULT; AGED; ALTERNATIVE SPLICING; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKIN-17; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-7; RNA, MESSENGER; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960173004     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01228.x     Document Type: Article

References (18)

1. Weinblatt ME, Keystone EC, Furst DE, et al Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2000; 48: 35-45.
2. Burmester GR, Mariette X, Montecucco C, et al Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007; 66: 732-9.
3. Weinblatt ME, Kremer JM, Bankhurst AD, et al A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999; 340: 253-9.
4. Elliott MJ, Maini RN, Feldmann M, et al Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994; 344: 1105-10.
5. Emery P, Fleischmann RM, Moreland LW, et al Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009; 60: 2272-83.
6. Badot V, Galant C, Nzeusseu Toukap A, et al Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther. 2009; 11: R57.
7. Goodwin RG, Friend D, Ziegler SF, et al Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell. 1990; 60: 941-51.
8. Pleiman CM, Gimpel SD, Park LS, et al Organization of the murine and human interleukin-7 receptor genes: two mRNAs generated by differential splicing and presence of a type I-interferon-inducible promoter. Mol Cell Biol. 1991; 11: 3052-9.
9. Arnett FC, Edworthy SM, Bloch DA, et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315-24.
10. van Gestel AM, Prevoo ML, van 't Hof MA, et al Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996; 39: 34-40.
11. De Bari C, Dell'Accio F, Tylzanowski P, et al Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001; 44: 1928-42.
12. Nzeusseu Toukap A, Galant C, Theate I, et al Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum. 2007; 56: 1579-88.
13. Liu X, Leung S, Wang C, et al Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nature Med. 2010; 16: 191-7.
14. van Roon JA, Verweij MC, Wijk MW, et al Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4(+) T cells and macrophages. Arthritis Rheum. 2005; 52: 1700-10.
15. van Roon JA, Hartgring SA, Wenting-van Wijk M, et al Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 66: 664-9.
16. Hartgring SA, van Roon JA, Wenting-van Wijk M, et al Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis. Arthritis Rheum. 2009; 60: 2595-605.
17. Faucher S, Crawley AM, Decker W, et al Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma. PLoS ONE. 2009; 4: e6690.
18. Rose T, Lambotte O, Pallier C, et al Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J Immunol. 2009; 182: 7389-97.